secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001082554-25-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63
-------------------------------------------------------------------------------

- Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).
- Tyvaso family revenue $466.3M (+25% YoY), with Tyvaso DPI up 33% to $302.5M and nebulized Tyvaso up 13% to $163.8M.
- R&D expense $149.0M (+43% YoY) driven by $30.0M milestone payments for drug delivery device technologies and adjustments to contingent consideration.
- Upcoming catalysts: TETON 2 readout in IPF, UKidney first-in-human study; IND filings planned for UHeart and UThymoKidney.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/0001082554-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/uthr-20250430.htm
  HTML page:      https://secwatch.observer/filing/0001082554-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer